MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

Search

Sanofi

Uždarymo kaina

48.73 0.87

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

48.34

Max

48.94

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.1B

2.8B

Pardavimai

2.4B

13B

P/E

Sektoriaus vid.

15.645

78.892

Pelno marža

21.276

Darbuotojai

82,878

EBITDA

2.3B

4.2B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+68.05% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-5.9B

117B

Ankstesnė atidarymo kaina

47.86

Ankstesnė uždarymo kaina

48.73

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Sanofi Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-24 11:40; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal -- Update

2025-12-24 11:17; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

Dynavax Shares Leap Premarket on Takeover by Sanofi

2025-12-24 06:55; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal

2025-12-15 10:11; UTC

Pagrindinės rinkos jėgos

Sanofi Shares Fall After Multiple Sclerosis Drug Gets Hit by Double Setback

2025-10-24 08:29; UTC

Uždarbis

Sanofi Earnings Get Boost From Dupixent, New Drugs as U.S. Talks Continue -- Update

2025-10-24 07:00; UTC

Uždarbis

Sanofi Earnings Driven by New Medicine Sales, Dupixent Performance

2025-12-24 17:08; UTC

Įsigijimai, susijungimai, perėmimai

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

2025-12-24 12:59; UTC

Įsigijimai, susijungimai, perėmimai

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

2025-12-24 06:41; UTC

Įsigijimai, susijungimai, perėmimai

Correct: Sanofi: Deal Expected to Have No Impact on 2025 Guidance

2025-12-24 06:19; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Acquisition to Close in 1Q of 2026

2025-12-24 06:19; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Deal Expected to Have on Impact on 2025 Guidance

2025-12-24 06:19; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Offering $15.50 a Share in Cash for Dynavax

2025-12-24 06:18; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Start Cash Tender Offer at Equity Value of $2.2B

2025-12-24 06:18; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Deal Adds Marketed Adult Hepatitis B Vaccine, Phase 1/2 Shingles Candidate

2025-12-24 06:17; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Buy Vaccine Company Dynavax Technologies

2025-12-24 06:16; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Buy Dynavax

2025-12-24 06:15; UTC

Įsigijimai, susijungimai, perėmimai

Press Release: Sanofi To Acquire Dynavax, Adding A Marketed Adult Hepatitis B Vaccine And Phase 1/2 Shingles Candidate To The Pipeline >SAN.FR

2025-12-15 15:03; UTC

Rinkos pokalbiai

Sanofi Multiple Sclerosis Trial Failure Leaves FDA Approval in Doubt -- Market Talk

2025-12-15 13:59; UTC

Karštos akcijos

Stocks to Watch Monday: iRobot, Tilray, EchoStar, Juventus -- WSJ

2025-12-15 11:18; UTC

Rinkos pokalbiai

Sanofi's Multiple Sclerosis Drug Fails Late-Stage Trial; Latest Pipeline Setback -- Market Talk

2025-12-15 09:53; UTC

Karštos akcijos

Stocks to Watch Monday: iRobot, EchoStar, Rocket Lab, Alibaba -- WSJ

2025-12-04 10:02; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi Completes Acquisition of Vicebio

2025-12-04 10:01; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi Buys Vicebio

2025-12-04 10:00; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi Completes Acquisition Of Vicebio >SAN.FR

2025-10-24 08:21; UTC

Rinkos pokalbiai
Uždarbis

Sanofi Results Reflect Improved Efficiency, Should Ease Margin Worries -- Market Talk

2025-10-24 07:56; UTC

Rinkos pokalbiai
Uždarbis

Sanofi's Dupixent Drives Growth, But Lantus Gains Set to Fade -- Market Talk

2025-10-24 05:30; UTC

Uždarbis

Sanofi 3Q Adj EPS EUR2.91

2025-10-24 05:30; UTC

Uždarbis

Sanofi Backs 2025 View

2025-10-24 05:30; UTC

Uždarbis

Analysts Saw Sanofi 3Q Business Net Profit at EUR3.29B

2025-10-24 05:30; UTC

Uždarbis

Sanofi 3Q Business Net Profit at EUR3.55B

Akcijų palyginimas

Kainos pokytis

Sanofi Prognozė

Kainos tikslas

By TipRanks

68.05% į viršų

12 mėnesių prognozė

Vidutinis 81.25 USD  68.05%

Aukščiausias 117.762 USD

Žemiausias 57 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sanofi kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

4 ratings

2

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

51.665 / 52.38Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
help-icon Live chat